child neurologist, and her research interests include pediatric clinical drug development for epilepsy and outcomes research of epilepsy patients, with a focus on treatment of epilepsy in children. She has clinical responsibility for the care of children enrolled in a clinical trial supported by Novartis for treatment of tuberous sclerosis patients with subependymal giant cell tumors of the brain. She is currently working on the Tuberous Sclerosis Alliance Natural History Database Project, funded by the Tuberous Sclerosis Alliance and the Centers for Disease Control and Prevention. She is a former Robert Wood Johnson Foundation Health Policy fellow. Dr. Bebin received her M.D. from the University of Mississippi School of Medicine in 1986. She completed her pediatric and neurology training at the Mayo Clinic in Rochester, Minnesota, and a fellowship in epilepsy at the University of Virginia. In 2005 she earned her M.P.A. from Harvard University-Kennedy School of Government.
Kirsten Bibbins-Domingo, Ph.D., M.D., M.A.S., is associate professor of medicine and epidemiology and biostatistics at the University of California, San Francisco, and an attending physician at San Francisco General Hospital. Dr. Bibbins-Domingo is an active researcher in preventive cardiology, the epidemiology of cardiovascular disease in young adults, and race and gender health and health care disparities. Her research has examined the development of cardiovascular risk factors in young adults, the effectiveness of screening and diagnostic tests for cardiovascular disease, and computer-simulated projections of future cardiovascular disease trends and the impact of public health and clinical interventions on cardiovascular disease prevention. Dr. Bibbins-Domingo served on the IOM Committee on Evaluation of the Presumptive Disability Decision-Making Process for Veterans from 2006 to 2007. She received her undergraduate degree in molecular biology and public policy from Princeton University and her medical degree, Ph.D. in biochemistry, and Masters of Clinical Research from the University of California, San Francisco.
Martha Constantine-Paton, Ph.D., is investigator at the McGovern Institute for Brain Research and Professor in the departments of Brain and Cognitive Sciences and Biology at the Massachusetts Institute of Technology (MIT). Previously, she was professor of biology at Yale University from 1985 until 1999, and a faculty member at Princeton University from 1976 through 1984, before joining MIT in 1999. Dr. Constantine-Paton studies activity-dependent brain development, glutamate receptor regulation, and physiology of the developing visual system in animal models. She is interested in the biochemical, structural, or genetic programs that cause the developing brain to lose its plasticity or to compensate for genetic mutations or trauma as the brain matures, possibly leading to loss of learning and memory or to